News Hub | News Direct

Online Capital Formation is a cost-effective and reliable alternative to fund businesses

KoreconX

With the latest happenings in the online banking world, venture capital funding is uncertain for the short term. Yet challenging times are when capital for innovation and development is needed most, leading companies at all stages to evaluate a different alternative for capital: the private market. Venture capital refers to investments made by venture capital firms, typically in early-stage startups or companies with high growth potential. Private capital, on the other hand, can come from a variety of sources, such as high-net-worth individuals, family offices, or private equity firms. These investments are made in countless industries and stages of development. Another difference that may lead entrepreneurs to opt for private capital is that, in most cases, venture capital firms take an active role in the management, while private capital investors do not - which allows entrepreneurs to retain control. Oscar A Jofre, Co-founder and CEO of KoreConX, explains. “Using digital platforms to raise funds from investors through JOBS Act regulations, companies have access to the exemptions from SEC registration such as RegA+, RegCF, RegD, and RegS, reaching a larger pool of investors beyond traditional VCs and private equity firms. These investments can be accessed by anyone, regardless of their net worth or accreditation status, and at any time, 24 hours a day, 365 days a year”. The SEC reports that $4.5T was raised in the private capital markets in 2022, of which the new JOBS Act regulations (RegCF, RegA+, RegD) accounted for $150.9B. Online capital formation platforms allow greater transparency, giving investors more information about an offering before they commit to investing in a particular business. This allows investors to make more informed decisions and reduces the risks associated with investing. Online platforms also typically charge lower fees than traditional VCs and private equity firms, making it a more cost-effective way to raise funds. Taken together, these advantages make online capital formation through RegA+, RegCF, RegS, or RegD attractive, viable alternatives to traditional venture capital for companies looking to access a wider pool of investors quickly and efficiently and with greater transparency. About KoreConX Founded in 2016, KoreConX is the first secure, All-In-One platform that manages private companies' capital market activity and stakeholder communications. With an innovative approach and to ensure compliance with securities regulations and corporate law, KoreConX offers a single environment to connect companies to the capital markets and now secondary markets. Additionally, investors, broker-dealers, law firms, accountants, and investor acquisition firms, all leverage our eco-system solution. Founded in 2016, KoreConX provides the first secure online infrastructure for private companies to conveniently and compliantly manage every aspect of their capital market activities, from issuing securities to shareholder relations. Investors, broker-dealers, law firms, accountants, and investor acquisition firms all leverage our ecosystem solution. KoreConX also maintains a large online library of educational content to help companies navigate their capital-raising journey. Contact Details Rafael Goncalves +1 888-885-0881 rafael@koreconx.com Company Website https://www.koreconx.com

March 21, 2023 12:59 PM Eastern Daylight Time

Image

Doceree takes the lead on transparency in programmatic Point-of-Care messaging by championing adoption of IAB standard

Doceree

Doceree today launched an industry-first initiative championing an existing standard that aims to authenticate messaging from point-of-care publishers within healthcare. The initiative mitigates any possible risks arising from ambiguity of the ecosystem, something not previously done within point-of-care media and media aggregators. Programmatic technology provides incredible convenience to showcase messages from life sciences brands to healthcare professionals (HCPs) on point-of-care platforms. However, the lack of transparency in the space has marred the progress of the entire ecosystem. In 2017, Interactive Advertising Bureau (IAB) introduced the ads.txt standard to bolster transparency by authenticating publisher platforms. The adoption of the standard is happening at a slow pace, especially so in the pharmaceutical industry, a sector which is still new to adopting digital tools and technologies to engage HCPs programmatically, compared to those in the consumer marketing space. As a leader in the point-of-care messaging category, Doceree is championing the adoption of the ads.txt standard in the healthcare industry. As part of its latest effort, the company has also released a white paper entitled “ Bolstering Transparency in Programmatic Pharma Messaging” that delves into the crucial role of ads.txt and how its adoption ensures transparency in programmatic media. “It is equally as important to effectively address the downsides of new technologies and empower companies to confidently use programmatic tools for their business growth and success. Being a leader in this ecosystem, it is our responsibility to do everything that bolsters transparency. This is what we are attempting to achieve with our adoption of IAB’s standard ads.txt practice,” said Harshit Jain MD, Founder and Global CEO, Doceree. “With Programmatic display ad spending estimated at nearly $150 billion this year, outpacing topline digital ad spending (according to emarketer US market forecast), it’s imperative that marketers know “who” and “where” are the authorized marketplaces. In healthcare marketing, we walk a very fine line to ensure that the right information is getting to the right patient, caregiver and HCP. This additional level of checks/balances is needed for brand safety and transparency. ” said Karima Sharif, Strategy Lead + Head of Inclusive Investments, Publicis Health Media. The Doceree White Paper can be downloaded here. About Doceree Doceree is a global platform building unprecedented solutions for healthcare professional (HCP) programmatic messaging with proprietary data tools. It facilitates messaging between life sciences brands and HCPs through an extensive global network of digital endemic and point-of-care platforms to programmatically deliver personalized communications to HCPs and transparent marketing campaign metrics at scale. To learn more, visit doceree.com. Contact Details Kyle Murray +91 70420 89805 kyle@kitehillpr.com Company Website https://doceree.com/us/

March 21, 2023 11:42 AM Eastern Daylight Time

Colorado pet owners say yes, they want access to mid-level veterinary professionals and telehealth

Vet Care Coalition

Responding to increasing costs and unavailability due to the state’s significant veterinary workforce shortage, four out of five Colorado pet owners say they would not hesitate to have their animal seen by a newly-created mid-level veterinary professional associate, similar in function and oversight to a physician assistant (PA). These are among the findings of an independent survey of Colorado pet owners announced by the Vet Care Coalition (VetCareCoalition.com), an expanding alliance of animal welfare organizations, veterinarians and technicians, pet owners, ranchers and other experts working to establish workable solutions to the state’s costly veterinary workforce shortage. The Vet Care Coalition is pursuing legislation in Colorado’s statehouse to achieve three common-sense initiatives toward addressing the state’s veterinary shortage: 1. Establishing a path for creation of a mid-level veterinary professional associate (VPA), similar to a physician assistant (PA) in human medicine. A VPA will be a master’s degree-level professional working under the supervision of a veterinarian to provide care such as examining pets, diagnosing minor conditions, performing routine surgeries and leading healthcare teams. These professionals will generate practice revenue while increasing overall workforce capacity, helping to increase patient availability while lowering costs. 2. Codifying the availability of veterinary care through telehealth services, which are increasingly used in human medicine. More than half of the state’s pet owners surveyed said they would be comfortable using virtual veterinary care for their animals. 3. Expanding the role of registered veterinarian technician specialists (VTS), with additional training and credentialing. “Vet tech” specialists are often underutilized in veterinary practices because Colorado regulations unreasonably limit what they can legally do. Expanding the role of a VTS will increase veterinary care capacity across the state while helping encourage retention at a time when many are leaving the sector due to burn-out and lack of professional growth. Colorado’s veterinary shortage is well-documented In 2021, the U.S. Department of Agriculture identified 25 rural and urban Colorado counties as having “veterinary shortage situations” in food animal medicine – a situation that contributes to higher prices while putting food safety at risk. In addition, the Veterinary Care Accessibility Project (AccessToVetCare.org) gave Colorado a score of only 58 out of 100, noting that veterinary care is nearly inaccessible in much of the state. The shortage has had a negative impact on pet owners and their animals across the country – and could get much worse. A Mars Veterinary Health study found that without solutions put in place soon, the U.S. will have 15,000 fewer veterinarians than it needs by 2030, leaving some 75 million pets without any veterinary care at all. The Colorado survey, conducted in mid-January by Corona Insights research firm, asked 556 pet owners across the state how they have been impacted by the veterinary shortage and gauged their initial comfort level with being seen by a VPA or via telehealth services. The research found that high veterinary costs generate the greatest level of concern and dissatisfaction among pet owners, with almost 25 percent saying high costs made them decide against taking their animals in for necessary care over the last year. The U.S. Dept. of Labor Consumer Price Index shows that between 1997 and 2022, veterinarian services steadily rose at almost twice the rate of inflation. Through 2021 and 2022 alone, the nation’s veterinary shortage contributed to service prices increasing by more than 13 percent. More than a quarter of survey respondents also said they were significantly challenged in finding and making timely appointments with veterinarians in their area. Logical and urgent need for a mid-level veterinary professional “While the human medical profession has embraced physician assistants for more than 50 years, veterinary medicine inexplicably still has no such mid-level professional position,” said coalition spokesperson Dr. Apryl Steele, past president of the Colorado Veterinary Medical Association (CVMA) and current CEO of the Dumb Friends League. “Animals will suffer until we fill this glaring need,” said Dr. Steele, “while Colorado’s veterinary workforce will continue to be severely overworked and understaffed.” The American Medical Association (AMA) officially recognized physician assistants in 1971, with the first PA certification tests implemented by the National Board of Medical Examiners two years later. “The VPA would not replace a veterinarian or a veterinary technician,” said Dr. Steele. “Rather, it will enhance a practice while providing credentialed veterinary technicians with a career path toward greater responsibility and compensation.” In Colorado’s USDA-identified veterinary shortage areas, VPAs will be allowed to work under indirect supervision to help increase access to care for food and fiber animals. “It’s important to understand that fully utilizing veterinary technicians and creating a mid-level veterinary PA are complementary options for solving Colorado’s veterinarian workforce shortage crisis,” said Dr. Steele. “We absolutely need both.” About the Vet Care Coalition The Vet Care Coalition is an expanding alliance that includes animal welfare organizations, veterinarians and technicians, pet owners, ranchers and other experts with a common goal to find workable solutions to the state’s costly veterinary workforce shortage. Organizational coalition members supporting the legislation include the Animal Welfare Association of Colorado (AWAC), Colorado Voters for Animals, the Dumb Friends League (DFL), Thrive Pet Healthcare, Humane Society of the Pikes Peak Region (HSPPR), Roice-Hurst Humane Society, Virtual Veterinary Care Association, Animal Policy Group, WellHaven Pet Health, Larimer Humane Society, the American Society for the Prevention of Cruelty to Animals (ASPCA) and Mars Petcare. Individual supporters include four former presidents of the Colorado Veterinary Medical Association (CVMA), as well as a growing number of veterinarians, practice owners and animal welfare advocates across the nation. For more information and to support efforts to increase access to veterinary care across Colorado, please visit www.vetcarecoalition.com. Contact Details Vet Care Coalition Steven Silvers +1 720-402-8820 ssilvers@vetcarecoalition.com

March 21, 2023 08:50 AM Mountain Daylight Time

Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy’s Laboratories To License and Commercialize COYA 302

Coya Therapeutics Inc.

By Kenneth Adams, Benzinga Coya Therapeutics, Inc. (NASDAQ: COYA) recently announced a worldwide agreement with Dr. Reddy’s Laboratories Limited. (BSE: 500124, NSE: DRREDDY) (NYSE: RDY) (NSEIFSC: DRREDDY), a global pharmaceutical company. Under this agreement, Coya will in-license the proposed Abatacept biosimilar of Dr. Reddy’s for the development of Coya’s combination product for neurodegenerative diseases, COYA 302. It is a dual biologic intended to suppress neuroinflammation via multiple immunomodulatory pathways, for the treatment of neurodegenerative conditions. COYA 302 is comprised of two components – COYA 301 and CTLA4-Ig. Coya will develop COYA 301. Under the terms of the Agreement, Coya has been granted an exclusive, royalty-bearing license to Dr. Reddy’s proposed biosimilar Abatacept for the development and commercialization of Coya 302 for the treatment of certain neurological diseases for sale in multiple territories including North and South America, the EU, United Kingdom, and Japan. As consideration for the license, Coya will pay a one-time non-refundable upfront fee to Dr. Reddy’s. In addition, Coya will owe tiered payments to Dr. Reddy’s based upon Coya’s achievement of certain developmental milestones. Coya will also owe royalties to Dr. Reddy’s on Net Sales of Coya 302 within its licensed territory on a tiered basis. The Agreement does not preclude Dr. Reddy’s from launching its proposed biosimilar Abatacept globally for approved indications post regulatory approval. Coya anticipates that it will file an IND for COYA 302 in the 2H of 2023 with the goal of initiating a phase 1b/2 trial in ALS (Amyotrophic Lateral Sclerosis ) soon thereafter. The Agreement also provides for the license of Coya 301, Coya’s low dose IL-2 to Dr. Reddy’s to permit the commercialization by Dr. Reddy’s of Coya 302 in territories not otherwise granted to Coya. Coya will receive royalties on Net Sales by Dr. Reddy’s in their territories based on the same tiered structure as Coya owes Dr. Reddy’s. The Agreement also allows Dr. Reddy’s and Coya to enter into a mutually satisfactory commercial supply agreement at an appropriate time. This article was originally published on Benzinga here. About Coya Therapeutics, Inc.Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (“Tregs”) to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions including neurodegenerative, metabolic, and autoimmune diseases, and this cellular dysfunction may lead to a sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system. Coya’s investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya’s therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. Coya’s 300 Series product candidates, COYA 301 and COYA 302, are biologic therapies intended to enhance Treg function and expand Treg numbers. COYA 301 is a cytokine biologic for subcutaneous administration intended to enhance Treg function and expand Treg numbers in vivo, and COYA 302 is a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages. These two mechanisms may be additive or synergistic in suppressing inflammation. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice Contact Details David S. Snyder David@coyatherapeutics.com Company Website https://coyatherapeutics.com/

March 21, 2023 09:55 AM Eastern Daylight Time

Aqua Cultured Foods to Begin Consumer Tastings of Alt-Seafood

AquaCultured Foods

Food tech startup Aqua Cultured Foods today announced it will begin consumer tastings of its seafood alternatives at its Chicago facility in advance of launching publicly through chef partners and foodservice distributors. Aqua will offer participants Aqua tuna rolls, shrimp dumplings and scallop crudo, and solicit feedback. Tastings will be held in Aqua’s West Loop, Chicago headquarters beginning in early April. Aqua is developing a range of alt-seafood from proprietary mycoprotein fermentation processes. A unique strain of fungi transforms plant-based ingredients into “seafood” with a realistic taste, texture, and appearance that can be used as a one-to-one replacement for animal seafood. The company is also producing minced fillings for applications such as dumplings, ravioli, and sushi rolls. “Public tasting events will help us fine-tune products and learn what preparations are most successful, which will also help us create new menu items with chef and restaurant partners,” said Aqua CEO Anne Palermo. “Participants should arrive hungry and prepare to be wowed, because they’ve never had plant-based seafood that’s this delicious and this convincing.” Those interested in joining a tasting panel can sign up at https://www.eventbrite.com/e/aqua-customer-taste-panels-tickets-565576212677?aff=Newsletter. Aqua’s calamari, shrimp, scallops, and filets of tuna and whitefish are created using fermentation processes that do not use any animal inputs, genetic altering or modification. Unlike plant-based processed foods formulated with starches and protein isolates, Aqua’s alt-seafood retains its naturally occurring fiber, protein, and other micronutrients. The rising demand for seafood has led to depleted fish populations, ecosystem damage, plastic waste, and unintended “bycatch” of non-target species due to commercial fishing. As fish farming increases, so does habitat destruction, pollution and diseases in wild fish populations, and the industry’s reliance on antibiotics and wild-caught fish for feed. For images visit https://app.box.com/s/wfbrvgraf2ty2b7by5h6ahjsaqrd8zx3. About Aqua Cultured Foods Aqua Cultured Foods is an innovative food technology startup developing the world’s first whole-muscle cut seafood alternatives created through microbial fermentation. Its novel technology produces a sustainable, complete protein source using only a fraction of the resources required by traditional aquaculture. As the first to develop realistic alt-seafood with fermentation, Aqua Cultured Foods occupies a unique position in the burgeoning alt-seafood market, as well as within the fermentation industry. The company’s mission is to mitigate global challenges such as overfishing, climate change and feeding the world’s expanding population with delicious, nutrient-rich foods. For more information visit https://www.aquaculturedfoods.com. Contact Details Evolotus PR Gary Smith +1 818-783-0569 gary@evolotuspr.com Company Website https://www.aquaculturedfoods.com

March 21, 2023 09:30 AM Eastern Daylight Time

Axis Medicare Advisors Partners with AmeriLife to Accelerate Growth

AmeriLife

AmeriLife Group, LLC (“AmeriLife”), a national leader in developing, marketing, and distributing life and health insurance, annuities and retirement planning solutions, announced today that it has partnered with Louisville, Ky.-based Axis Medicare Advisors, one of the nation’s top designers and distributors of market-leading Medicare Supplement and ancillary health products for Aetna. Per the agreement, terms of the deal were not disclosed. “Our business was built on ‘trust,’ and today, I’m excited to announce that we, too, have found a trusted partner in AmeriLife to propel Axis forward,” said James “Jamie” Sarno, president and CEO of Axis Medicare Advisors. “Our team is excited to join this industry leader. We look forward to tapping into AmeriLife’s incredible leadership and resources to continue delivering excellence for Axis agents and their clients.” Founded in 1991, Axis has grown from a small outfit into a leading Medicare solutions shop known for its deep Medicare Supplement and ancillary health product portfolio, best-in-class customer service, and expert knowledge of the evolving and complex Medicare space. Now, Axis will have full access to AmeriLife’s best-in-class technology, tools and resources and leading distribution platform, positioning it for significant growth and long-term success. Relatedly, Sarno will join AmeriLife as vice president of Medicare Supplement and Specialty Health and will report to AmeriLife’s Chief Distribution Officer of Health, Scotty Elliott, effective April 3. Sarno brings over 35 years of experience in the Medicare Supplement market to AmeriLife, and as a national advisor for Aetna, he has supported the design of proprietary products that remain core to AmeriLife’s holistic health offering. With Sarno’s departure, Ronnie Lapinsky will assume day-to-day operational oversight of Axis. “Ronnie has been a loyal friend and valuable asset at Axis for more than 21 years,” added Sarno. “There’s no one better suited to continue Axis’s legacy of protecting seniors and helping them with the ever-changing landscape of Medicare.” “We’re thrilled to welcome Axis Medicare Advisors to AmeriLife’s Health family and, at the same time, Jamie to our growing Health leadership bench,” said Elliott. “Both represent the continued, incredible run of growth for our Health distribution. We can’t wait to work with Jamie to elevate our Medicare Supplement and health specialty strategy while also helping Ronnie and his team at Axis expand and grow their business to new heights.” ### About AmeriLife AmeriLife’s strength is its mission: to provide insurance and retirement solutions to help people live longer, healthier lives. In doing so, AmeriLife has become recognized as the leader in developing, marketing, and distributing life and health insurance, annuities and retirement planning solutions to enhance the lives of pre-retirees and retirees across the United States. For more than 50 years, AmeriLife has partnered with top insurance carriers to provide value and quality to customers served through a distribution network of over 300,000 insurance agents and advisors and 120 marketing organizations and insurance agency locations nationwide. For more information, visit AmeriLife.com, and follow AmeriLife on Facebook and LinkedIn. About Axis Medicare Advisors Founded in 1991 and based in Louisville, Ky., Axis Medicare Advisors is a leading Medicare and specialty health insurance agency serving seniors nationwide. Axis’s team of professionals offers unparalleled customer support, expert advice and a portfolio of health solutions from some of the biggest insurance carriers in the market. For more information, visit AxisMedicareAdvisors.com. Contact Details Media Jeff Maldonado +1 321-297-1112 jmaldonado@amerilife.com Partnership Inquiries Patrick Nichols +1 727-726-0726 pnichols@amerilife.com Company Website https://amerilife.com/

March 21, 2023 09:00 AM Eastern Daylight Time

KORECONX PRESENTS AT LSI EMERGING MEDTECH SUMMIT CONNECTING INNOVATORS & INVESTORS

KoreconX

KoreConX is pleased to announce once again its supporting sponsorship for the LSI Emerging Medtech Summit 2023, which takes place in Dana Point, California, starting next week. This is the first edition of the year, with the mission to connect innovators and investors. Oscar A Jofre, Co-founder and CEO of KoreConX, is a proud sponsor, supporter and speaker at the event. “Both KoreConX and Life Science Intelligence (LSI) are innovator’s companies. That is why it is so natural for us to be connected. Companies need to raise capital compliantly to keep the medtech ecosystem blooming, and we can definitely help. We want to be part of the solution”. LSI is part of the medtech ecosystem led by KoreConX. This ecosystem brings experts together in driving innovation while helping medtech leaders access the community, capital and insights to enable growth. As an essential part of this vertical, LSI’s team of market researchers, economists, and analysts provides valuable insights and data to help investors and executives make informed decisions. LSI Emerging Medtech Summit 2023 will take place from March 20th to 23rd, and attendees can participate in person or online. Registration is still open on the website, with limited spots remaining. For the full schedule, speakers and keynotes, as well as for any registrations, visit the event website. About KoreConX Founded in 2016, KoreConX is the first secure, All-In-One platform that manages private companies' capital market activity and stakeholder communications. With an innovative approach and to ensure compliance with securities regulations and corporate law, KoreConX offers a single environment to connect companies to the capital markets and now secondary markets. Additionally, investors, broker-dealers, law firms, accountants and investor acquisition firms, all leverage our eco-system solution. Founded in 2016, KoreConX provides the first secure online infrastructure for private companies to conveniently and compliantly manage every aspect of their capital market activities, from issuing securities to shareholder relations. Investors, broker-dealers, law firms, accountants, and investor acquisition firms all leverage our ecosystem solution. KoreConX also maintains a large online library of educational content to help companies navigate their capital-raising journey. Contact Details Rafael Goncalves +1 888-885-0881 rafael@koreconx.com Company Website https://www.koreconx.com

March 20, 2023 03:50 PM Eastern Daylight Time

Image

News Release

NuggMD Launches Its Leading Marijuana Telemedicine Service in Louisiana

NuggMD

NuggMD, the nation's leading medical marijuana telemedicine platform, today announced it has launched its service in Louisiana. For $179, Louisiana residents can now use NuggMD’s platform to speak with a medical professional and access cannabis to treat qualifying medical conditions. As in some other states, medical cannabis is legal in Louisiana, but the implementation of the law has been slow, which has created uncertainty and inconsistencies for both businesses and consumers. Louisiana legislators passed H.B.697 last summer, which allows physicians to recommend cannabis via telemedicine for both follow-up and initial evaluations. However, the state’s medical board refused to change regulations to fully enact the new legislation, citing sections of existing law that it claimed conflicted with the legislative intent of the Act. Legislators spent months in tense debate with the medical board, attempting to convince it to allow physicians to use telemedicine for cannabis recommendations, as the law stipulates. Upon reaching an impasse, State Rep. Joseph Marino (I) sent a request to Louisiana Attorney General Jeff Landry objecting to the board's stance and requesting an opinion. Landry's response was that the law is clear and that a physician may see a patient via telemedicine if they deem it medically appropriate and follow all other guidance. In his opinion, Landry responded by pointing out that: The distinction between a recommendation and a prescription is valid and was affirmed by case law. Therefore, the prohibition against prescribing certain controlled substances via telemedicine does not apply to the recommendation of marijuana. The legislature clearly intended to make this distinction when it changed the state's medical marijuana laws to remove the references to "prescribing" cannabis and replace them with "recommending" cannabis. "Stated succinctly," he wrote, "neither Louisiana's statutory law nor the regulations promulgated by LSBME currently require physicians to conduct an in-person visit prior to recommending therapeutic marijuana to a patient through telemedicine." Alex Milligan, co-founder and CMO of NuggMD, commented, "Attorney General Landry's clarification is commendable because it finally allows physicians to deliver care to patients in a safe way that eliminates risk from unnecessary exposure to illness and difficult travel." “It's not uncommon to see regulators push back on bold new legislation, especially in an area as contentious as cannabis. When a regulatory environment is constantly in flux, businesses have to make difficult decisions about how and where to operate in light of these constantly changing directives. This holds true for most any industry, not just cannabis," said Milligan. NuggMD co-founder and CEO Kim Babazade added, "We chose to wait to offer our platform to physicians in Louisiana until we had complete clarity on this issue. Our physicians and patients are the most important consideration for us, so we strongly focus on compliance for everyone's protection." NuggMD's platform is available from 8 am until 10 pm local time, seven days a week. No appointment is needed, and patients who are deemed not to qualify for Louisiana’s medical cannabis program won't be charged for their evaluation. Since its founding in 2015, NuggMD has helped more than 1,000,000 patients access medical marijuana in nearly half of the nation's states. About NuggMD NuggMD is the nation's leading medical marijuana technology platform, serving patients in California, Connecticut, Georgia, Illinois, Iowa, Louisiana, Maine, Maryland, Massachusetts, Michigan, Missouri, Montana, Nevada, New Jersey, New York, Ohio, Oklahoma, Pennsylvania, Texas, Vermont, Virginia, and West Virginia. They've connected over 1,000,000 patients face-to-face with their new medical marijuana doctors via their state-of-the-art telemedicine platform. They believe every human being has the right to explore the benefits of medical cannabis and are fully committed to helping each patient explore every option in their journey to wellness. For further information, visit NuggMD.com. Contact Details Andrew Graham andrew.g@getnugg.com Company Website http://www.nuggmd.com

March 20, 2023 12:09 PM Eastern Daylight Time

A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats

NanoViricides, Inc.

By Ernest Dela Aglanu, Benzinga With the COVID pandemic still ongoing, having claimed more than 6.8 million lives from about 758 million cases and crippling the global economy, there are several reasons why drug research and development related to the COVID virus remains highly relevant and necessary. Ongoing drug development by companies such as NanoViricides Inc. (NYSEAMERICAN: NNVC) is vital because new variants of the virus keep emerging and viral infections, hospitalizations and deaths continue at a much greater rate than even pandemic influenza years despite the roll-out of vaccines from players like Novavax Inc. (NASDAQ: NVAX), Moderna Inc. (NASDAQ: MRNA), Oxford– AstraZeneca plc (LON: AZN), and Pfizer Inc. (NYSE: PFE)–BioNTech As new virus variants continue to develop, researchers must stay ahead of the curve to identify and combat them. Given the fast-evolving nature of the virus, early detection of these new variants is thought to be crucial in controlling their spread and preventing further outbreaks. However, with significantly reduced testing worldwide, it is now widely understood that a new damaging variant may not be readily identified before it spreads. Even after 3 years of pandemic, do we have effective drugs that could stop the next variant? Unfortunately, we don’t have even one safe and effective drug that does not come with a lot of limitations. This is why the need to treat current infections and also to better prepare for future pandemics has spurred a new wave of investment and interest in COVID research and development. NanoViricides has recently reported that it is very close to testing its drug candidate NV-CoV-2 to treat SARS-CoV-2 infection in human clinical trials. Thus the Company is nearing an inflection point in its lifecycle, with the first clinical trials of its unique and novel nanomedicines platform. Human clinical trials are now becoming imminent — NanoViricides will no longer be a R&D/Drug Discovery company, but will soon become a clinical-stage pharma company. Traders and investors are taking note of what could be a unique opportunity. NanoViricides, a growing innovator in nanomedicine and antiviral therapies, has been maturing its nanomedicine technology in developing drugs against many viruses for over 15 years, and their most recent developments could potentially prove to be market-disrupting with implications for treating dozens of viruses worldwide. All these years of research and development are coming together for NanoViricides, now, positioning it to potentially become a major player in the antivirals space. NanoViricides has reported: A platform technology that enables it to develop drugs rapidly against many viruses as shown with many candidates in pre-clinical studies against a number of viruses. Technology to make drugs that variants of the virus cannot escape because no matter how much the virus changes, it uses the same receptor, and this company’s technology for first-in-class drugs is based on making copies of that unique receptor. A novel mechanism of action, enabling first-in-class drugs against viruses. Technology to make broad-spectrum antiviral drugs. For example, the company has shown in preclinical studies that its COVID drug works against all the tested coronaviruses. The ability to manufacture first-in-class drugs at scale to make finished drug products for clinical trials of their lead candidate against COVID in its own cGMP compliant manufacturing facility. The COVID drug, NV-CoV-2, has been formulated and tested in the form of Oral Gummies, and also as Oral Syrup - to help COVID-positive patients, including children and older patients who need more accessible treatments. Read the latest report on NanoViricides here. Dosing And Effectiveness NV-CoV-2 Reportedly Superior An additional problem for current COVID cases is that available COVID drugs like remdesivir by Gilead (NASDAQ: GILD), molnupiravir by Merck (NYSE: MRK), and to a lesser extent, Paxlovid by Pfizer (NYSE: PFE) face the challenge of limited dosing for safety reasons — which is a part of why they have limited effectiveness and limitations on use — increasing dosage would not give increased benefit thus limiting the drugs’ capability. Unlike these drugs, the very high safety numbers that NV-CoV-2 has demonstrated in rat studies indicate that patients might be able to take more of the Company’s COVID drug to achieve greater effectiveness when their sickness is more severe. This is expected to be validated in imminent human clinical trials. Once NanoViricides proves that its COVID drug is safe in clinical trials, the company’s entire platform of nanotechnology would essentially be validated as being capable of developing safe drugs. Additionally, assuming NanoViricides demonstrates strong effectiveness of the COVID drug in clinical trials, similar to the strong effectiveness they have reported in their pre-clinical studies, that would validate the Company’s pre-clinical approach in studying effectiveness for developing clinical candidates, and will likely have strong positive implications for the other drug candidates in their pipeline too. As NanoViricides’ reported effective and safe solutions for battling against the COVID pandemic move into the clinic, heralding its official entry as a pharmaceutical drug maker, the story doesn’t stop there. Once the platform is proven, the Company could be well positioned to develop solutions to battle other current and future pandemics as well. The company has drugs nearing clinical stage for treating Shingles and Herpes Viruses (HSV-1 and HSV-2). And it says it will be forging ahead to further develop candidates to battle HIV, Ebola/Marburg, Monkeypox, and other viruses. With the global antiviral therapy market valued at $48.1 billion in 2018 and estimated to garner $79.8 billion by 2026, rising at a compound annual growth rate (CAGR) of 6.7% from 2019 to 2026, NanoViricides could be strategically placed to participate in such significant market size and growth while potentially revolutionize the industry with the Company’s unique biomimetic technology. Head to https://profiles.smallcapsdaily.com/nnvc/ to read more about NanoViricides’ technology. This article originally appeared on Benzinga here. About NanoViricides NanoViricides, Inc. (the "Company") (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Our lead drug candidate is NV-HHV-101 with its first indication as dermal topical cream for the treatment of shingles rash. In addition, we are developing a clinical candidate for the treatment of COVID-19 disease caused by SARS-CoV-2 coronavirus. The Company cannot project an exact date for filing an IND for this drug because of its dependence on a number of external collaborators and consultants.The Company is now working on tasks for completing an IND application. The Company is currently pursuing two separate drug candidates for the treatment of COVID-19 patients. NV-CoV-2 is our nanoviricide drug candidate that does not encapsulate Remdesivir. NV-CoV-2-R is our other drug candidate that is made up of NV-CoV-2 with Remdesivir encapsulated in it. The Company believes that since Remdesivir is already US FDA approved, our drug candidate encapsulating Remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.The Company intends to re-engage into an IND application to the US FDA for NV-HHV-101 drug candidate for the treatment of shingles once its COVID-19 project moves into clinical trials, based on resources availability. The NV-HHV-101 program was slowed down because of the effects of recent COVID-19 restrictions, and re-prioritization for COVID-19 drug development work.The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for poxviruses if the initial research is successful. The Company's technology is based on broad, exclusive, sub-licensable, field licenses to drugs developed in these areas from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Contact Details NanoViricides, Inc. +1 203-937-6137 info@nanoviricides.com Company Website http://www.nanoviricides.com

March 20, 2023 09:45 AM Eastern Daylight Time